Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi).

Alexandra Leary,Albin Jeanne,Marion Etiennot,Aubéri Henry,Coralie Drelon,Christophe Schneider,Aurélie Moniot,Stéphane Dedieu

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.5568

IF: 45.3

2024-06-01

Journal of Clinical Oncology

Abstract:5568 Background: There is an urgent need for novel therapies for patients relapsing post-PARPi. CD47 is an attractive target due to its overexpression in OC, particularly under PARPi treatment, and its association with shorter survival and immune evasion. While most studies have focused on the CD47/SIRPa interaction (“don’t eat me” signal), our recent data from the randomized CHIVA trial (NCT01583322) uncovered the relevance of TSP-1, a matrix glycoprotein associated with poor prognosis, as a primary CD47-interacting ligand [ASCO 2023]. The TAX2 peptide selectively disrupts TSP-1 binding to CD47. Our aim was to investigate whether inhibiting the CD47/TSP-1 axis with TAX2 could overcome PARPi resistance in a syngeneic mouse model of BRCA2 mutant OC. Methods: Biodistribution studies of fluorescent TAX2 peptide were carried out in mice bearing ovarian tumors tracked through fluorescence molecular tomography. To assess the efficacy of TAX2 and/or PARPi (olaparib) treatment, we used ID8 cells harboring Trp53 -/- and Brca2 -/- mutations, as a pertinent syngeneic representation of intraperitoneal high-grade serous TP53 and BRCA2 mutated OC. Olaparib was administrated at 50 mg/kg orally daily, while TAX2 was administrated at 30 to 100 mg/kg intravenously thrice weekly. Survival curves were compared using the Gehan-Breslow-Wilcoxon's test. Results: We confirmed that TAX2 peptide binds directly to human TSP-1 with K D of 11 μM. In mice bearing tumors, TAX2 correlated with TSP-1 expression with prolonged accumulation at tumor sites, but none in healthy tissues. Using a relevant peritoneal carcinomatosis model exhibiting PARP inhibitor resistance, we demonstrated that administration of TAX2 alone significantly extended survival. Interestingly, post-olaparib administration of TAX2 substantially reduced tumor burden, even at the lowest TAX2 dosing, and prolonged survival (median survival: 44 vs 38 days). Remarkably, sequential use of TAX2 increased animal survival even under treatment conditions allowing olaparib efficacy. Indeed, post-olaparib discontinuation, mice survival increased from 10.6 to 15.7 days with administration of TAX2. This sequential approach improved the median survival to 56 days. Conclusions: Our findings propose TAX2 as a promising strategy for patients relapsing on PARP inhibitors. TAX2 displayed a selective biodistribution pattern in mice, concentrating at tumor sites. Our study showcased that while TAX2 alone exhibited significant but modest activity in PARPi-naive mice, its efficacy significantly increased post-PARPi exposure, irrespective of PARPi duration. A first in human trial in the post-PARP setting is planned.

oncology